Back to top

Analyst Blog

NPS Pharmaceuticals (NPSP - Analyst Report) announced that the label of its sole marketed product, Gattex, has been updated by the FDA. The U.S. label of the drug now includes long-term data from STEPS 2 (n=88) — the two-year open-label extension of the 24-week phase III international STEPS study.

Gattex is available in the U.S. since Feb 2013 for treating adults with short bowel syndrome, dependent on parenteral support. The STEPS 2 study proved the effectiveness of Gattex for long-term use.  

Data from the study revealed additional and clinically meaningful reductions in the volume and days/week of parenteral support requirements in patients who continued treatment with the drug beyond two years. In addition, data from the extension study showed that 13 patients achieved complete independence from parenteral support. Moreover, long-term Gattex treatment did not result in any new unexpected safety issues.

We remind investors that the FDA accepted NPS Pharma’s marketing application seeking to update Gattex’s label in Nov 2013. The favorable FDA decision should augment the drug’s sales potential.

NPS Pharma expects to add another product – Natpara (rhPTH [1-84]) – to its portfolio later in the year. The company is looking to get Natpara, which has been granted orphan drug status in the U.S. and EU, approved for treating hypoparathyroidism. The candidate is currently under review in the U.S. A decision from the FDA on Natpara is expected by Oct 24, 2014. Approval of Natpara would reduce the company’s dependence on Gattex for growth.

NPS Pharma carries a Zacks Rank #5 (Strong Sell). Better-ranked stocks in the healthcare sector include Regeneron Pharmaceuticals (REGN - Analyst Report), Biogen Idec (BIIB - Analyst Report) and The Medicines Company (MDCO - Analyst Report). All three stocks sport a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 2.99 +2.75%
CTPARTNERS… CTP 16.21 +2.08%
CHINA BIOLO… CBPO 46.93 +1.88%
THE PANTRY… PTRY 20.93 +1.65%
NN INC NNBR 28.43 +1.46%